TerminatedNot Applicable

Clinical Evaluation of the QuantiFERON CMV Assay

Stopped: Business decision.

United States8 participantsStarted 2018-11-15

Plain-language summary

Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult CMV D+/R- liver, kidney, heart, pancreas, lung, intestinal, or combined transplant recipients that are 18 years of age or older. * Scheduled to receive between 3 to 6 months of antiviral prophylaxis * Provide Informed Consent Exclusion Criteria: * Subjects less than 18 years old * Scheduled to receive longer than 6 months or shorter than 3 months of prophylaxis * Unable to provide Informed Consent

What they're measuring

Change in time to CMV Infection between sub-groups of QF-CMV assay classifications.

Timeframe: At time of prophylaxis termination, +1 month from termination, +2 months from termination

Trial details

NCT IDNCT03502161

SponsorQIAGEN Gaithersburg, Inc

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2020-05-15

View on ClinicalTrials.gov More CMV trials